LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

Home・Lista de Ações・Ardelyx Inc

Ardelyx Inc

Fechado

SetorSaúde

6.6 -2.22

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

6.57

Máximo

6.82

Indicadores-chave
By Trading Economics
Rendimento	-37M -38M
Vendas	-31M 94M
EPS	-0.15
Margem de lucro	-39.805
Funcionários	489
EBITDA	-42M -32M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+144.84% upside

Dividendos
By Dow Jones
Próximos Ganhos	3 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	334M 1.8B
Abertura anterior	8.82
Fecho anterior	6.6

Sentimento de Notícias

By Acuity

26%

74%

60 / 347 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

3.62 / 3.95 Suporte e Resistência

Ardelyx Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

10 de mai. de 2026, 23:47 UTC

Conversa de Mercado

Gold Falls on Renewed Inflation Concerns -- Market Talk

10 de mai. de 2026, 23:44 UTC

Conversa de Mercado

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

10 de mai. de 2026, 23:38 UTC

Conversa de Mercado

Oil Rises Amid Signs of Ongoing Middle East Tensions -- Market Talk

10 de mai. de 2026, 23:14 UTC

Conversa de Mercado

Australia's Political Map Continues to Be Redrawn -- Market Talk

10 de mai. de 2026, 22:22 UTC

Aquisições, Fusões, Aquisições de Empresas

Elevra Lithium: Expects Deal to Close in 1Q FY27

10 de mai. de 2026, 22:21 UTC

Aquisições, Fusões, Aquisições de Empresas

Elevra Lithium: Expects to Received About $71 Million Before Fees, Taxes in Cash

10 de mai. de 2026, 22:21 UTC

Aquisições, Fusões, Aquisições de Empresas

Elevra Lithium Agrees to Sell Ewoyaa Lithium Project Stake to Zhejiang Huayou Cobalt

10 de mai. de 2026, 10:21 UTC

Ganhos

Saudi Aramco Profit Jumps Despite War Disrupting Shipping Routes -- WSJ

9 de mai. de 2026, 06:05 UTC

Ganhos

Our Innodata Stock Pick Smashed Earnings Expectations. Stay Long. -- Barrons.com

8 de mai. de 2026, 23:55 UTC

Ganhos

Review & Preview: Still Going Strong -- Barrons.com

8 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

8 de mai. de 2026, 20:49 UTC

Ganhos

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8 de mai. de 2026, 20:25 UTC

Ganhos

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 de mai. de 2026, 19:43 UTC

Ganhos

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8 de mai. de 2026, 19:43 UTC

Ganhos

Cencosud 1Q Net $115M

8 de mai. de 2026, 19:20 UTC

Conversa de Mercado

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8 de mai. de 2026, 19:18 UTC

Ganhos

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8 de mai. de 2026, 19:16 UTC

Ganhos

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 de mai. de 2026, 19:08 UTC

Ganhos

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 de mai. de 2026, 19:05 UTC

Ganhos

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8 de mai. de 2026, 19:02 UTC

Conversa de Mercado

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8 de mai. de 2026, 18:51 UTC

Ganhos

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8 de mai. de 2026, 18:49 UTC

Ganhos

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 de mai. de 2026, 18:41 UTC

Ganhos

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8 de mai. de 2026, 17:38 UTC

Conversa de Mercado

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8 de mai. de 2026, 17:14 UTC

Ganhos

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8 de mai. de 2026, 17:04 UTC

Conversa de Mercado

Zcash Caps Off Parabolic Week -- Market Talk

8 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

8 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

8 de mai. de 2026, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

Comparação entre Pares

Variação de preço

Ardelyx Inc Previsão

Preço-alvo

By TipRanks

144.84% parte superior

Previsão para 12 meses

Média 16.6 USD 144.84%

Máximo 19 USD

Mínimo 13 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Ardelyx Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

5 ratings

Comprar

Manter

Vender

Com base em 5 analistas que deram avaliações de ações para Ardelyx Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

3.62 / 3.95Suporte e Resistência

Recent bearish events outweigh bullish events.

All events are bearish.

Recent bearish events outweigh bullish events.

Sentimento

By Acuity

60 / 347 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Ardelyx Inc

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.